JCAR-020

**JCAR-020** is an investigational **MUC16-directed armored CAR-T cell therapy** developed in the Juno Therapeutics program family. It consists of genetically engineered autologous T cells expressing a chimeric antigen receptor targeting **mucin 16**, also known as **CA-125**, a tumor-associated antigen frequently overexpressed in ovarian cancer and other solid tumors. The construct is additionally engineered to deliver **interleukin-12**, making it an armored CAR-T approach intended to enhance T-cell activation and anti-tumor activity within the immunosuppressive tumor microenvironment. Based on the available context, the program appears to have been explored as an early-stage oncology cell therapy candidate, particularly for **ovarian cancer**, but no approved brand name or marketed indication was identified.

Other names

MUC16-targeting IL-12 armored CAR T cell therapyMUC-16-targeting IL-12 armored CAR T cell therapyMUC 16-targeting IL-12 armored CAR T cell therapy